Skip to main content
Fig. 8 | Virology Journal

Fig. 8

From: Highly efficacious and safe neutralizing DNA aptamer of SARS-CoV-2 as an emerging therapy for COVID-19 disease

Fig. 8

Aptamer AYA2012004_L does not elicit an immunogenic response in human peripheral blood mononuclear cells (hPBMCs). Human PBMCs were stimulated with or without AYA2012004_L, LPS, ODN 1826 and LPS+ODN 1826 at 37 \(^\circ\)C for 24 and 48 h. The amount of cytokines secreted from PBMCs were assessed by the LEGENDplex Human Inflammation kit. Soluble analytes were quantified using flow cytometry and analyzed with BioLegend’s LEGENDplex™ software. The p values were determined with one-way ANOVA, Dunnett’s multiple comparison test. * denotes \(p<\)0.05, ** denotes \(p<\)0.01 and *** denotes p<0.001

Back to article page

Virology Journal

ISSN: 1743-422X